Trial Profile

A Randomized, Two-Period Crossover Study in Healthy Volunteers to Establish the Bioequivalence of Two Formulations of BG00012.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Jun 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dimethyl fumarate (Primary)
Indications Multiple sclerosis; Rheumatoid arthritis
Focus Pharmacokinetics
Sponsors Biogen

Most Recent Events

13 Oct 2012 Results presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
11 Sep 2012 Primary endpoint 'bioequivalence, assessed by area-under-the-drug-concentration-time-curve' has been met.
11 Sep 2012 Results presented at the 16th Congress of the European Federation of Neurological Societies.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com